Sugi Predict

Sugi Predict / Targets / BCR

BCR

Breakpoint cluster region protein · P11274 · BCR on Sugi Atlas →

123,904 patent compounds predicted against BCR, 86,280 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9469 SCHEMBL9469 0.76 18/20
SCHEMBL1365 SCHEMBL1365 1.00 17/20
SCHEMBL1255 SCHEMBL1255 0.80 17/20
SCHEMBL1430 SCHEMBL1430 1.00 16/20
SCHEMBL1442 SCHEMBL1442 1.00 16/20
SCHEMBL1465 SCHEMBL1465 1.00 16/20
SCHEMBL9338 SCHEMBL9338 1.00 16/20
SCHEMBL9485 SCHEMBL9485 1.00 16/20
SCHEMBL9565 SCHEMBL9565 1.00 16/20
SCHEMBL9763 SCHEMBL9763 1.00 16/20
SCHEMBL10208 SCHEMBL10208 0.82 16/20
SCHEMBL9862 SCHEMBL9862 0.79 16/20
SCHEMBL1762 SCHEMBL1762 0.74 16/20
SCHEMBL1522 SCHEMBL1522 1.00 15/20
SCHEMBL9642 SCHEMBL9642 1.00 15/20
SCHEMBL9838 SCHEMBL9838 1.00 15/20
Imatinib Imatinib (SCHEMBL3827) 1.00 14/20
Imatinib Imatinib (SCHEMBL8217) 1.00 14/20
SCHEMBL9197 SCHEMBL9197 1.00 14/20
SCHEMBL9588 SCHEMBL9588 0.98 14/20

Clinical trials — most relevant to BCR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation PHASE4COMPLETED
Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia PHASE2/PHASE3COMPLETED
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia PHASE3RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) PHASE2COMPLETED
Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia PHASE2UNKNOWN
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML PHASE1/PHASE2COMPLETED
Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response PHASE2COMPLETED
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib PHASE2RECRUITING
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia PHASE2ACTIVE_NOT_RECRUITING
Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy PHASE2COMPLETED
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia PHASE2ACTIVE_NOT_RECRUITING
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE) PHASE2NOT_YET_RECRUITING
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia PHASE2UNKNOWN
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) PHASE1NOT_YET_RECRUITING
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia PHASE1COMPLETED
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study nanCOMPLETED
Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log nanUNKNOWN
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia nanRECRUITING
Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment nanCOMPLETED
Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm nanUNKNOWN
TIGIT in Patients With Chronic Myeloid Leukemia nanUNKNOWN
Effect of 2nd Gen TKI in CML nanCOMPLETED
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults nanRECRUITING
Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia nanCOMPLETED
Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia nanUNKNOWN
Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes nanUNKNOWN
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia nanCOMPLETED
Allogeneic SCT for CML, TKI Failure After TKI Failure nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BCR binder may also engage these)

ProteinNameSimilarity
F1LXF1 — 1.000 F1LXF1 →
Q6PAJ1 — 1.000 Q6PAJ1 →
P49797 — 0.985 P49797 →
Q8WXG6 — 0.984 Q8WXG6 →
Q80U28 — 0.984 Q80U28 →
Q92625 — 0.983 Q92625 →
Q66H91 — 0.983 Q66H91 →
CBL E3 ubiquitin-protein ligase CBL 0.982 landscape →
Q66T02 — 0.982 Q66T02 →
Q6ZWB6 — 0.982 Q6ZWB6 →
Q9BSQ5 — 0.982 Q9BSQ5 →
P22682 — 0.982 P22682 →
Q9Z1N9 — 0.982 Q9Z1N9 →
Q6DRP4 — 0.982 Q6DRP4 →
P0C6S7 — 0.982 P0C6S7 →
Q9UPW8 — 0.982 Q9UPW8 →
Q50H33 — 0.981 Q50H33 →
Q7Z628 — 0.981 Q7Z628 →
Q92622 — 0.981 Q92622 →
Q8BWW9 — 0.981 Q8BWW9 →
Q8K2Y9 — 0.981 Q8K2Y9 →
Q9UPU7 — 0.981 Q9UPU7 →
Q80U40 — 0.981 Q80U40 →
Q8BIZ1 — 0.981 Q8BIZ1 →
P28028 — 0.981 P28028 →
Q69ZK0 — 0.981 Q69ZK0 →
Q9Z206 — 0.981 Q9Z206 →
O14795 — 0.981 O14795 →
Q9Z1T4 — 0.980 Q9Z1T4 →
Q62768 — 0.980 Q62768 →